Arthneeti
Anuh Pharma LtdQ3 FY21

Anuh Pharma Ltd Q3 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹90.3P/E: 21.5Market Cap: ₹951 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • The company expects a 20% to 25% year-on-year growth in top line (sales/revenue) over the next 4 to 5 years.
  • New products are targeted to contribute at least 25% of total revenue within the next 3 years.
  • Quantity-wise sales in regulated markets are expected to increase progressively year-on-year, with regulatory products currently contributing 17.5% and expected to grow 10% annually.
  • Capacity expansion plans include increasing manufacturing capacity from 1200 to 1500 metric tonnes by FY22, aiming for 80-85% utilization by 2023.
  • Fastest growing products anticipated over 2 years: Azithromycin, Sulfadoxine, and Gliclazide.
  • The company plans a 30% growth in top line and bottom line post recent expansions, maintaining an EBITDA margin around 15%.
  • Ambroxol approved for European regulatory markets; more regulatory approvals expected in 3-4 years post validation.

See what Anuh Pharma Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. - The company is focusing on organic growth, including capacity expansion (from 1200 to 1500 metric tonnes) and product development. - There are plans for inorganic growth via acquisitions, but only if the right candidate is found; no fundraising details were shared. - The company is studying the listing criteria for NSE, expected to take 6-9 months, but no mention of raising equity in this context. - Overall, the management emphasizes internal cash flows and investment plans funded through own means rather than government schemes or external fundraising. Therefore, based on the transcript, there is no announced or planned debt or equity fundraising at this time.

See what Anuh Pharma Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes
  • During FY 2021-22, Anuh Pharma plans to invest an additional ₹4 crores in capital expenditure.
  • This capex aims to increase manufacturing capacity from 1,200 metric tonnes per year to 1,500 metric tonnes.
  • The company had previously spent around ₹70 crores for expansion commissioned in December 2019.
  • There are ongoing validation batches and R&D activities on new products like Gliclazide, Ambroxol Hydrochloride, and Sulfadoxine at the new plant.
  • The company is also exploring inorganic growth through acquisitions but is yet to identify the right candidate; the plan is to pursue this within the next 1.5 years.
  • No current plans for entering CRAMS (Contract Research and Manufacturing Services); focus remains on API manufacturing.

Track Anuh Pharma Ltd — get its next earnings analysis in your feed

Margin guidance

Category 3
  • The company expects top line growth of 20% to 25% year-on-year for the next 4-5 years.
  • EBITDA margin target is around 15%, with an average EBITDA margin of 15% already achieved in FY21 despite higher depreciation.
  • For FY22, management conservatively expects 25-30% growth in both top line and bottom line.
  • New regulatory product sales are expected to grow about 10% year-on-year, with regulatory sales already contributing 17.5% and expected to increase to 25%.
  • Profit margins on regulatory sales are higher, with EBITDA margins of 30-35% vs 14-15% for non-regulatory sales.
  • Expansion plans include increasing capacity from 1200 to 1500 metric tonnes by FY22, aiming for 80-85% utilization.
  • The management is confident of continuing steady growth in profits and EPS driven by new product launches and increased regulatory market penetration.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Anuh Pharma Limited. However, some relevant points that indirectly relate to orders and market expectations include: - The company expects fast growth in key products like Azithromycin, Sulfadoxine, and Gliclazide in the next 2 years. - Regulatory sales, including European approvals and WHO prequalification products, are expected to increase year-on-year by at least 10%. - The expanded manufacturing capacity is planned to increase from 1200 MT to 1500 MT during FY22, with utilization expected to reach around 80-85% by FY22-23. - The company is targeting 20-25% year-on-year top-line growth over the next 4-5 years. - They have been able to maintain a broad client base of approximately 350 customers to ensure steady demand. - No specific numeric order book or pending order values are disclosed in the transcript.

How does Anuh Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisAnuh Pharma Ltd
Rev 2Mar 3
See where Anuh Pharma Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Anuh Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Anuh Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY21) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Continue your research

What Anuh Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • IOL Chemicals (Q1 FY27)

    Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…

  • Innova Captab Ltd (Q1 FY27)

    The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…

  • Glenmark Pharma. (Q1 FY27)

    Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…

  • Strides Pharma Science Ltd (Q1 FY27)

    markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…

Compare:vs Sun Pharmaceutical Industries Ltdvs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →